GPR55 and myeloid sarcoma: Altogether, our findings identify CB<sub>1</sub>R/GPR55 heteromers as novel modulators of OLG resilience and highlight their potential as therapeutic targets for promoting neuroprotection and remyelination in demyelinating diseases such as MS.